Prevention with HIV Infected Persons seen in Primary Care Settings: This initiative was designed to address the need for interventions targeting HIV-positive individuals in clinical care, to prevent transmission to uninfected individuals and to prevent re-infection among people who are already infected with the virus.
The Special Projects of National Significance (SPNS) program awarded grants to one evaluation center and 15 demonstration sites.
The evaluation center provides leadership in the design and evaluation of interventions that will have maximum impact on the theory, practice and policy of HIV prevention in primary health care settings.
The 15 clinical demonstration sites were funded to implement and evaluate prevention interventions with HIV-infected individuals seen in primary care settings.
The questions to be investigated include, among others: (1) Are provider-driven interventions in clinical settings effective?; (2) What specific models are most effective with different target populations (e.g.
men of color who have sex with other men, heterosexual women, rural drug users, etc.)? An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Abuse Treatment in HIV Primary Care: Based on new legislation and the availability of buprenorphine treatment, the Buprenorphine Initiative was designed to determine the effectiveness of integrating buprenorphine opioid abuse treatment into HIV primary care settings.
This initiative began in September 2004 and is comprised of 10 demonstration sites coordinated by a technical assistance/evaluation center.
The initiative is directed towards persons with HIV in the primary care setting who also have substance abuse issues.
As a demonstration project, this initiative seeks to determine the feasibility and/or effectiveness of integrating buprenorphine opioid abuse treatment into HIV primary care settings.
The ultimate goal is to improve the health of HIV substance abusers.
The Department of Health and Human Services is the Federal government's principal agency for protecting the health of all Americans and providing essential human services, especially to those who are least able to help themselves.
In FY 07 there were 39 continuation grants and 18 new awards grants; in FY 08 there will be 34 continuation grants and approximately 17 new award grants.
Uses and Use Restrictions
The SPNS Program supports the development of innovative models of HIV care to respond to the emerging needs of individuals receiving assistance under the Ryan White HIV/AIDS Treatment Modernization Act of 2006.
SPNS evaluates the effectiveness of these models, and promotes the replication of successful models.
Areas of evaluation include design, implementation, utilization, costs, and health related outcomes of effective models.
The SPNS Program also supports special programs to develop standard electronic client information data systems to enable Ryan White Program grantees to report client level data.
Proposals are expected to adequately define and justify the needs, innovative nature, and evaluation methodology of the proposed model of services.
Funds shall be used to create and/or evaluate innovative models of HIV care that would likely not exist nor be evaluated without SPNS Program support, or that would extend the care model to previously underserved or unserved populations.
Funds under the SPNS Program cannot be used for: charges that are billable to third party payers (e.g., private health insurance, prepaid health plans, Medicaid, Medicare); construction of new facilities or capital improvements to existing facilities; to purchase or improve land; cash payments to intended service recipients, as opposed to various incentives to encourage participation in evaluation activities.
Eligible entities: only those eligible for funding under Parts A-D of the Ryan White HIV/AIDS Treatment Modernization Act of 2006.
Adults, women, children and families with HIV disease.
Applicants should review the individual HRSA Guidance documents issued under this CFDA program for any required proof or certifications which must be submitted prior to or simultaneous with submission of an application package.
Aplication and Award Process
This program is eligible for coverage under E.O.
12372, "Intergovernmental Review of Federal Programs." An applicant should consult the office of official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review.
Grant applications and required forms for this program can be obtained from Grants.gov. Please visit the Grants.gov Web site at www.grants.gov to both find and apply for all Federal grant opportunities. All qualified applications will be forwarded to an objective review committee which will make funding recommendations to the Associate Administrator for the Bureau of HIV/AIDS. The Associate Administrator has the authority to make final selections for awards.
Applications will be objectively reviewed based on published evaluation review criteria, assigned a numerical score, and rank ordered for funding.
Public Health Service Act, Title XXVI, Part F, as amended, Public Law 109-415; Ryan White HIV/AIDS Treatment Modernization Act of 2006.
Range of Approval/Disapproval Time
From 4 to 6 months.
Formula and Matching Requirements
This program has no statutory formula or matching requirements.
Length and Time Phasing of Assistance
Grants will generally be awarded with 60-month project periods and five 12-month budget periods; some grants may have more limited 12, 24 or 36 month project periods.
Post Assistance Requirements
A final progress report is due 90 days after the end of the project period.
In addition, a Financial Status Report is due within 90 days after the close of each budget period and after the end of the project period.
In accordance with the provisions of OMB Circular No. A-133 (Revised, June 27, 2003), "Audits of States, Local Governments, and Nonprofit Organizations," nonfederal entities that expend financial assistance of $500,000 or more in Federal awards will have a single or a program-specific audit conducted for that year. Nonfederal entities that expend less than $500,000 a year in Federal awards are exempt from Federal audit requirements for that year, except as noted in Circular No. A-133.
All records must be maintained until expiration of 3 years from the date of submission of the final expenditure report. If questions remain following the 3-uear period, such as those raised as a result of an audit or an on-going enforcement action, recipients must retain records until the matter is completely resolved.
(Grants) FY 07 $25,000,000; FY 08 $25,000,000; and FY 09 est not available.
Range and Average of Financial Assistance
$75,000 to $600,000; $300,000.
Regulations, Guidelines, and Literature
This program is subject to the provisions of 45 CFR Part 92 for State, local and tribal governments and 45 CFR Part 74 for institutions of higher education, hospitals, other nonprofit organizations and commercial organizations, as applicable.
Regional or Local Office
Adan Cajina, Chief, Demonstration and Evaluation Branch, Division of Science and Policy, HIV/AIDS Bureau, Health Resources and Service Administration, 5600 Fishers Lane, Room 7C-07, Rockville, MD 20857. Telephone Number: (301) 443-3180.
Grants Management Office: Rick Goodman, Director, Division of Grants Management Operations, Health Resources and Services Administration, Department of Health and Human Services, 5600 Fishers Lane, Room 11A-16. Health Services Branch: Telephone: (301) 443-2385; Research and Training Branch: Telephone: (301) 443-3099; Government and Special Focus Branch: Telephone: (301) 443-3288.
Criteria for Selecting Proposals
Evaluation criteria vary and are based on the grant initiative. However, evaluation criteria generally include some or all of the following: Factor 1: Adequacy of demonstrated knowledge of the local HIV service delivery system and the adequacy of the justification of need for the proposed model within the community and target population to be served by the project. Factor 2: Extent of the feasibility and clarity of the description, appropriateness, innovative quality, and potential for evaluation, replication, and dissemination of the proposed model. Factor 3: Comprehensiveness of the program plan as described in clearly stated goals, time-limited and measurable objectives for each goal, activities directly related to each objective, and a timeline that shows the schedule of activities and production of materials that corresponds to milestones stated in the objectives and program evaluation. Factor 4: Thoroughness, feasibility and appropriateness of the project's evaluation design from a methodological and statistical perspective. Factor 5: Extent to which the applicant demonstrates past involvement with disseminating information about HIV service delivery by describing dissemination activities to date (e.g., presenting and publishing findings through reports and papers, training, or technical assistance). Factor 6: Competency of the applicant organization in terms of fiscal, program management, and evaluation.